The company will use the funds to commercialize a biomarker for colon cancer. Applied Proteomics’ system looks at activity patterns in the proteins encoded by a person’s genome rather than just the genome alone to detect early signs of cancer.
The $28 million contribution came from Genting Berhad, an investment holding company in Malaysia, as well as existing investors.
More Articles on Gastroenterology:
Vice & Associates Clinical Research Expands Gastroenterology Suite, Team Members
Drs. Rayees Nizam, Thomas Lee Join Associated Gastroenterologists of Central New York
5 Recent GI-Driven Center Openings & Plans
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.